All In Biotech

Drug Trial Radar · NCT05481333

A Trial to Learn if REGN7999 is Safe and Well Tolerated, and How it Works in the Body of Healthy Participants

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of REGN7999, a TMPRSS6 Antagonist, in Healthy Adult Subjects

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

64

Actual

Start

Oct 24, 2022

Primary completion

Aug 29, 2023

Study completion Aug 29, 2023

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Aug 1, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of the study is to evaluate the safety and tolerability of single ascending intravenous (IV) and subcutaneous (SC) doses of REGN7999 in healthy adult participants. The secondary objectives of the study are: * To characterize the drug concentration profile of single doses of IV or SC REGN7999 * To assess the immunogenicity of single ascending SC or IV doses of REGN7999

Conditions

  • Healthy

Interventions

  • REGN7999Drug

    Ascending IV or SC dose administered per protocol

  • PlaceboDrug

    Ascending IV or SC dose administered per protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of treatment emergent adverse events (TEAEs) in participants treated with REGN7999 or placeboTime frame: Through the end of study visit, week 20
  2. Incidence and severity of TEAEs in participants treated with REGN7999 or placeboTime frame: Through the end of study visit, week 26

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Drug Research Unit Gent

    Ghent, Belgium

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.